title: A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
abstract: BACKGROUND
  Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment.
  
  
  METHODS
  A retrospective review of 183 patients submitted to second-line therapy has been performed to identify prognostic factors, provides useful information for patients counseling and generates hypotheses for future studies. Inclusion criteria were: cytological or histologic diagnosis of pancreatic adenocarcinoma and prior gemcitabine-including chemotherapy. Any age, performance status (PS) and chemotherapy regimen were considered.
  
  
  RESULTS
  One hundred and eighty-three patients (106 males; 168 metastatic; median age 62 years; median PS 1; 63 submitted to prior curative surgery, 32 to prior radiotherapy) with a median previous progression-free survival (PFS) of 6.7 months were included. Median and 6-month PFS after initiation of salvage therapy were 3.0 months and 20%. Median, 1 and 2 years, overall survival after initiation of salvage therapy were 6.2 months, 17 and 4%, respectively. Previous PFS, CA19.9 levels and age independently predicted OS.
  
  
  CONCLUSIONS
  Re-challenge with gemcitabine and 5-fluorouracil administration may have a role in selected patients.
authors.affiliation: Department of Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy. reni.michele@hsr.it
authors.forename: M
authors.initials: M
authors.lastname: Reni
authors.forename: R
authors.initials: R
authors.lastname: Berardi
authors.forename: A
authors.initials: A
authors.lastname: Mambrini
authors.forename: L
authors.initials: L
authors.lastname: Pasetto
authors.forename: S
authors.initials: S
authors.lastname: Cereda
authors.forename: V D
authors.initials: VD
authors.lastname: Ferrari
authors.forename: S
authors.initials: S
authors.lastname: Cascinu
authors.forename: M
authors.initials: M
authors.lastname: Cantore
authors.forename: E
authors.initials: E
authors.lastname: Mazza
authors.forename: S
authors.initials: S
authors.lastname: Grisanti
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D017211:Treatment Failure; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000093542:Gemcitabine